首页|期刊导航|中国食品药品监管|创新药上市后安全性主动监测

创新药上市后安全性主动监测OA

Active Post-Marketing Safety Surveillance of Innovative Drugs:Practice and Challenges of Real-World Studies

中文摘要英文摘要

随着医药科技的飞速发展,基于新机制、新靶点的创新药不断涌现,为患者提供了更多治疗希望.本文综述了真实世界研究在创新药上市后安全性主动监测中的实践应用与面临的挑战.首先,梳理真实世界研究相关指导原则,重点分析了国内相关指导原则及国际人用药品注册技术协调会指导原则的核心要求;其次,通过典型案例,从监测技术创新、特定药品安全性评价及监管决策支持3个层面展现了真实世界研究的实践价值;再次,针对当前创新药安全性信号识别与因果确认的核心挑战,系统剖析了从信号检出到因果推断的完整证据链;最后,综述了从传统关联性评价到前沿因果推断方法的方法学进展,并提出了优化数据来源、强化数据治理、人机结合检测、加强多学科协作等综合应对措施.基于当前主动监测的不足之处,可考虑从强化顶层设计与哨点医院网络建设、推动多源医疗数据整合与人工智能技术应用等方面着手,构建一个反应迅速、运行高效、管理规范的创新药上市后安全性主动监测新体系,为完善我国的药物警戒体系提供参考.

With the rapid advancement of medical science and technology,innovative drugs based on new mechanisms and new targets continue to emerge,offering patients more treatment options and hope.This article reviews the practical applications and challenges of real-world studies in active post-marketing safety surveillance of innovative drugs.First,it reviews relevant regulatory guidelines on real-world studies,with a focus on the core requirements of relevant domestic guidelines and the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH).Second,it demonstrates the practical value of real-world studies from three dimensions:innovation in surveillance technologies,safety evaluation of specific drugs,and support for regulatory decision-making with typical cases.Third,in response to the core challenges of safety signal detection and causal confirmation for innovative drugs,this article systematically analyzes the complete evidence chain from signal detection to causal inference.Finally,it reviews methodological advances from traditional association assessment to emerging causal inference methods,and proposes comprehensive measures including optimizing data sources,strengthening data governance,implementing human-machine collaborative detection,and enhancing multidisciplinary collaboration.In view of the current limitations of active surveillance,it is recommended to strengthen top-level design and sentinel hospital networks,promote the integration of multi-source medical data and the application of artificial intelligence technologies,and build a new active post-marketing safety surveillance system for innovative drugs that is responsive,efficient,and well-regulated,thereby providing references for improving China's pharmacovigilance system.

李橙妍

上海市药品和医疗器械不良反应监测中心

医药卫生

创新药上市后安全性真实世界研究主动监测

innovative drugspost-marketingsafetyreal-world studiesactive surveillance

《中国食品药品监管》 2026 (9)

70-79,10

2025年中国药品监督管理研究会课题(2025-Y-Y-014)

10.3969/j.issn.1673-5390.2026.09.007

评论